151 related articles for article (PubMed ID: 38277755)
1. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
2. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
3. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
4. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
5. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
6. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
8. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
9. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma.
Wan X; Yan Z; Tan Z; Cai Z; Qi Y; Lu L; Xu Y; Chen J; Lei T
Neuroendocrinology; 2022; 112(5):417-426. PubMed ID: 34034260
[TBL] [Abstract][Full Text] [Related]
11. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of difficult to treat macroprolactinomas.
Sahakian N; Castinetti F; Dufour H; Graillon T; Romanet P; Barlier A; Brue T; Cuny T
Expert Rev Endocrinol Metab; 2019 May; 14(3):179-192. PubMed ID: 30913932
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
14. The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the
Vroonen L; Beckers A; Camby S; Cuny T; Beckers P; Jaffrain-Rea ML; Cogne M; Naves L; Ferriere A; Romanet P; Elenkova A; Karhu A; Brue T; Barlier A; Pétrossians P; Daly AF
Front Endocrinol (Lausanne); 2023; 14():1242588. PubMed ID: 37711900
[TBL] [Abstract][Full Text] [Related]
15. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
Recouvreux MV; Camilletti MA; Rifkin DB; Díaz-Torga G
J Endocrinol; 2016 Mar; 228(3):R73-83. PubMed ID: 26698564
[TBL] [Abstract][Full Text] [Related]
16. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
17. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
Wu N; Zhu D; Li J; Li X; Zhu Z; Rao Q; Hu B; Wang H; Zhu Y
J Endocrinol Invest; 2023 Aug; 46(8):1573-1587. PubMed ID: 36853491
[TBL] [Abstract][Full Text] [Related]
18. Resistant prolactinomas.
Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
20. MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas.
Xiao Z; Wang Z; Hu B; Mao Z; Zhu D; Feng Y; Zhu Y
Biochem Biophys Res Commun; 2019 Nov; 520(1):79-85. PubMed ID: 31582213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
